Mixed lineage leukemia (MLL)-fusion proteins can induce acute myeloid leukemias (AMLs) from either hematopoietic stem cells (HSCs) or granulocyte–macrophage progenitors (GMPs), but it remains ...
Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...
Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...
A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in the field ...
The researchers can identify infected mice that develop leukemia, isolate the white blood cells and ... in clinical samples from patients with AML and myelodysplastic syndromes.
Syndax Pharmaceuticals has announced that its Phase II trial of revumenib achieved its primary endpoint in certain patients with relapsed or refractory acute myeloid leukaemia (AML). Despite this ...
and cell death. Abnormalities in tyrosine kinases are common in AML, and constitute an attractive therapeutic target. An example is given by the balanced chromosomal translocations (TEL-Abl ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback